stella
beta
Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis — Stella
Recruiting
Back to Juvenile Dermatomyositis trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
China
Children's Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang
View full record on ClinicalTrials.gov